Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Verastem, Inc.
Vanderbilt-Ingram Cancer Center
NantCell, Inc.
National Cancer Institute (NCI)
Humanetics Corporation
University of Pittsburgh
Case Comprehensive Cancer Center
Acrotech Biopharma Inc.
University of Texas Southwestern Medical Center
Milton S. Hershey Medical Center
Dartmouth-Hitchcock Medical Center
Holy Cross Hospital, Florida
Radiation Therapy Oncology Group
UNC Lineberger Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Amgen
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Northwestern University
Northwestern University